Table 3:

Multivariable-adjusted association between receipt of guideline concordant care and breast cancer mortality among 7046 women diagnosed with stage I–III breast cancer in metro-Atlanta (2010–2014).

Guideline Therapy	Events	HR (95% CI)*
Guideline Concordant Care
Discordant	131	1.60 (1.26, 2.04)
Concordant	178	Reference
Chemotherapy
Discordant	61	1.39 (1.02, 1.90)
Concordant	261	Reference
Radiation
Discordant	38	1.92 (1.36, 2.71)
Concordant	284	Reference
Endocrine therapy
Discordant	74	1.70 (1.29, 2.24)
Concordant	266	Reference
Anti-HER2 therapy
Discordant	32	1.79 (1.20, 2.67)
Concordant	308	Reference
Any three modalities
Discordant	62	2.23 (1.59, 3.12)
Concordant	278	Reference

^*Adjusted for race, age, stage, SES, subtype, and insurance